Product Highlight - PRECEDEX PREMIX

03 Mar 2023
Product Highlight - PRECEDEX PREMIX

         Intensive Care Unit Sedation1

  • Dexmedetomidine is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. Dexmedetomidine should be administered by continuous infusion not to exceed 24 hours.
  • Dexmedetomidine has been continuously infused in mechanically ventilated patients prior to extubation, during extubation, and post-extubation. It is notnecessary to discontinue Dexmedetomidine prior to extubation.

    Procedural Sedation1
    • Dexmedetomidine is indicated for sedation/anxiolysis of non-intubated patients prior to and/or during surgical and other procedures.

    Reference:
    1. Dexmedetomidine hydrochloride (Precedex Premix) LDP Revision Date: 07 March 2022.






Pfizer, Inc. 19/F-20/F 8 Rockwell Building,
Hidalgo Drive Rockwell Center, Poblacion,
Makati City, 1210 Metro Manila Philippines
GCMA Code: PP-PDX-PHL-0174
November 2022 For Healthcare Professionals Only

Scan the QR Code or type the URL in your browser to
        find the Full Prescribing Information of
         DEXMEDETOMIDINE [PRECEDEX]
                    https://www.pfi.sr/4Rc 

Related MIMS Drugs